EP4704913A2 - Conjugués anticorps-médicament utilisant de nouveaux systèmes lieur-charge utile pour le ciblage amélioré d'antigènes associés au cancer - Google Patents

Conjugués anticorps-médicament utilisant de nouveaux systèmes lieur-charge utile pour le ciblage amélioré d'antigènes associés au cancer

Info

Publication number
EP4704913A2
EP4704913A2 EP24725410.5A EP24725410A EP4704913A2 EP 4704913 A2 EP4704913 A2 EP 4704913A2 EP 24725410 A EP24725410 A EP 24725410A EP 4704913 A2 EP4704913 A2 EP 4704913A2
Authority
EP
European Patent Office
Prior art keywords
seq
paired
antibody
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24725410.5A
Other languages
German (de)
English (en)
Inventor
Gonçalo BERNARDES
Nuno Prego RAMOS
Mariangela NATALE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2306706.9A external-priority patent/GB202306706D0/en
Priority claimed from GBGB2306730.9A external-priority patent/GB202306730D0/en
Application filed by Biontech SE filed Critical Biontech SE
Publication of EP4704913A2 publication Critical patent/EP4704913A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un conjugué anticorps-médicament (ADC) est fourni et comprend un anticorps qui se lie au sialyl Tn (STn) ou à un glycane terminé par un acide sialique à liaison alpha 2,6, conjugué à un médicament par l'intermédiaire d'un lieur, le lieur comprenant un lieur clivable, et le médicament comprenant un agent inhibiteur de croissance qui est l'exatécan, le déruxtécan ou un dérivé correspondant. Le conjugué anticorps-médicament (ADC) de l'invention comprend un lieur clivable par la glucuronidase, par exemple, le lieur comprend une fraction β-glucuronide, telle que représentée dans la formule I : Formule (I). Le conjugué anticorps-médicament (ADC) comprend un lieur qui est lié, ou est modifié pour se lier, au médicament par l'intermédiaire d'une liaison carbamate, ou un lieur qui est lié, ou est modifié pour se lier, au médicament par l'intermédiaire d'une liaison de sel d'ammonium quaternaire. Le conjugué anticorps-médicament (ADC) peut comprendre un lieur qui est PEGylé avec un groupe comprenant du polyéthylène glycol (PEG). De nouveaux lieurs destinés à être utilisés dans des ADC sont également décrits.
EP24725410.5A 2023-05-05 2024-05-02 Conjugués anticorps-médicament utilisant de nouveaux systèmes lieur-charge utile pour le ciblage amélioré d'antigènes associés au cancer Pending EP4704913A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2306706.9A GB202306706D0 (en) 2023-05-05 2023-05-05 Antibody-drug conjugates employing novel linker-payload systems for enhanced targeting of cancer-associated glycan antigens
GBGB2306730.9A GB202306730D0 (en) 2023-05-06 2023-05-06 Antibody-drug conjugates employing novel linker-payload systems for enhanced targeting of cancer-associated antigens
PCT/EP2024/062120 WO2024231224A2 (fr) 2023-05-05 2024-05-02 Conjugués anticorps-médicament utilisant de nouveaux systèmes lieur-charge utile pour le ciblage amélioré d'antigènes associés au cancer

Publications (1)

Publication Number Publication Date
EP4704913A2 true EP4704913A2 (fr) 2026-03-11

Family

ID=91076529

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24725410.5A Pending EP4704913A2 (fr) 2023-05-05 2024-05-02 Conjugués anticorps-médicament utilisant de nouveaux systèmes lieur-charge utile pour le ciblage amélioré d'antigènes associés au cancer

Country Status (3)

Country Link
EP (1) EP4704913A2 (fr)
CN (1) CN121219019A (fr)
WO (1) WO2024231224A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121401440A (zh) * 2025-10-21 2026-01-27 北京晟日昭阳生物科技有限公司 一种靶向治疗胰腺癌的抗体偶联物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216846B2 (fr) 1985-04-01 1995-04-26 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
NZ758049A (en) * 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
FI3900742T3 (fi) * 2014-09-11 2024-08-16 Seagen Inc Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
KR20180090290A (ko) * 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
WO2018103739A1 (fr) 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 Conjugué anticorps-médicament, procédé de préparation, intermédiaire, composition pharmaceutique et utilisation
WO2018160909A1 (fr) * 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Composés interagissant avec le glycane et méthodes d'utilisation
PT110526B (pt) 2018-01-26 2021-02-04 Univ Nova De Lisboa Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
AU2021335257A1 (en) * 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
EP4331616A4 (fr) 2021-05-13 2026-03-18 Univ Tsinghua Conjugué anticorps-médicament, procédé de préparation s'y rapportant et utilisation associée
JP2024521629A (ja) 2021-06-02 2024-06-04 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗体薬物コンジュゲート、及びその調製方法及びその使用
GB2619976A (en) 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法

Also Published As

Publication number Publication date
WO2024231224A2 (fr) 2024-11-14
CN121219019A (zh) 2025-12-26
WO2024231224A3 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
JP7775358B2 (ja) 単一ドメイン血清アルブミン結合タンパク質
AU2017267793B2 (en) Single chain variable fragment CD3 binding proteins
US20240277863A1 (en) Antibody-urease conjugates for therapeutic purposes
JP2020048567A (ja) イメージングのための新規ｐｄ−ｌ１結合ポリペプチド
Constantinou et al. Site-specific polysialylation of an antitumor single-chain Fv fragment
CN113527487A (zh) 抗人b7-h3的单克隆抗体及其应用
JP2018524296A (ja) Ｃｄ１２３抗体及びその複合体
JP2018515087A (ja) 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
EP4299589A1 (fr) Anticorps anti-cd73 humain et son utilisation
CN115461354B (zh) 用于分子缀合或改造的串联重复癌症靶向肽及其在癌症治疗诊断学中的用途
CN118480117B (zh) 工程化抗体和包含工程化抗体的抗体-药物偶联物
CA2891190A1 (fr) Conjugues polypeptide derive d'aprotinine-anticorps
US20200368364A1 (en) Cysteine peptide-enabled antibodies
CN113045659B (zh) 抗cd73人源化抗体
EP4704913A2 (fr) Conjugués anticorps-médicament utilisant de nouveaux systèmes lieur-charge utile pour le ciblage amélioré d'antigènes associés au cancer
CN119874942B (zh) 一种放射性蛋白偶联药物及其应用
CN119731200A (zh) 经电荷修饰设计的重复结构域及其用途
CN118660909A (zh) 亲和力增强的抗ecm纳米抗体-细胞因子融合体及其应用
JP2026514252A (ja) がん関連抗原の標的化を増強するための新規リンカー－ペイロード系を用いた抗体－薬物コンジュゲート
HK40117905A (zh) 用於治疗目的的抗体-脲酶缀合物
CN120965878A (zh) 一种抗nmda受体抗体及其应用
KR20230163487A (ko) 항egfr 항체의 방사성 복합체 및 방사성 의약
KR20240149030A (ko) 항-bcam 항체 및 항체-약물 접합체
CN116813778A (zh) 一种靶向中期因子mdk的d4纳米抗体及其衍生物和应用
CN117377690A (zh) 抗egfr抗体的放射性复合物和放射性药物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251121

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR